# Phase III Clinical Trial of Y-2 Sublingual Tablets in the Treatment of Acute Ischemic Stroke

> **NCT04950920** · PHASE3 · COMPLETED · sponsor: **Peking University Third Hospital** · enrollment: 914 (actual)

## Conditions studied

- Stroke

## Interventions

- **DRUG:** Y-2 sublingual tablets
- **DRUG:** d-borneol

## Key facts

- **NCT ID:** NCT04950920
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-28
- **Primary completion:** 2022-08-10
- **Final completion:** 2022-11-14
- **Target enrollment:** 914 (ACTUAL)
- **Last updated:** 2023-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04950920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04950920, "Phase III Clinical Trial of Y-2 Sublingual Tablets in the Treatment of Acute Ischemic Stroke". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT04950920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*